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(http://creativecommosyndrome (DS). We report a deep phenotyping study undertaken over 7 years in a participant with DS
who was nondemented at baseline but developed dementia after 5 years.
Methods: Throughout the course of the study, the participant was seen 4 times (2010, 2013, 2015,
and 2017). Multimodal neuroimaging, including three serial scans of [11C]-PiB-PET, four structural
magnetic resonance imagings, as well as a [18F]-AV1451 scan, was interpreted alongside detailed
neuropsychological assessments over the study period.
Results: Amyloid beta accumulation preceded the onset of dementia and cognitive decline, which in
turn corresponded to the predominant deposition of tau in temporoparietal cortices.
Discussion: Until now, data on the longitudinal trajectories of amyloid accumulation, tau pathol-
ogy, and brain atrophy over multiple time points remain scarce in DS. This case report highlights
the potential for deep phenotyping imaging to elucidate the substrates of cognitive decline in DS,
although further longitudinal studies are necessary to clarify the relative contributions of both
amyloid and tau.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Down syndrome (DS) is the most common neurodevelop-
mental disorder caused by the presence of trisomy 21 (1:800
live births). The extra copy of amyloid precursor protein
(APP) gene on chromosome 21 is associated with a 4- to
5-fold overexpression of amyloid precursor protein that re-
sults in increased cerebral accumulation of its proteolyticthor. Tel.: 01223 465216.
m24@medschl.cam.ac.uk
/j.dadm.2019.04.006
he Authors. Published by Elsevier Inc. on behalf of the Alzh
ns.org/licenses/by/4.0/).product of b-amyloid (Ab) [1]. Consequently, Alzheimer’s
disease (AD) pathologies (i.e., Ab and neurofibrillary tau
tangles) and comorbid dementia are highly prevalent in peo-
ple with DS by the fifth decade [2]. Clarifying the neuropath-
ological substrates that underpin cognitive decline may help
identify suitable therapeutic interventions and optimization
of clinical trials. Until now, data on the longitudinal trajec-
tories of amyloid accumulation, tau pathology, and brain at-
rophy over multiple timepoints remain scarce. We report a
deep-phenotyping case study undertaken over 7 years (4
timepoints) in a participant with DS who was nondemented
at baseline butwho developed clinical dementia after 5 years.eimer’s Association. This is an open access article under the CC BY license
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scans of [11C]-PiB-PET, four structural magnetic resonance
imaging (MRI) scans, and a [18F]-AV1451 scan, were inter-
preted alongside in-depth cognitive assessments over the
study period.
2. Methods
2.1. Clinical assessment and cognitive profile
The participant enrolled into the study when he was
48 years old in 2010. His cognitive function was assessed
using the CAMCOG, a validated tool for assessing cogni-
tive decline in DS. He was also assessed using the Cam-
bridge Examination for Mental Disorders of Older people
with Down’s Syndrome and Others with Intellectual Dis-
abilities informant interview, a neuropsychological assess-
ment battery designed for diagnosing dementia in
accordance with the International Classification of
Diseases-10 criteria for dementia in DS [3]. The studies
that he was part of were all approved by the National
Research Ethics Committee of East of England and the
Administration of Radioactive Substances Advisory Com-
mittee.2.2. Multimodal imagingTable 1
Raw scores achieved in different functional areas evaluated in the
CAMCOG across 7 years: Scores collected over 4 timepoints
Cognitive variables T1 T2 T3 TX* T4 Max score
Orientation total 10 10 12 12 12 12
Comprehension 7 9 6 7 2 9
Expression 16 18 17 18 14 18
Language total 23 27 23 25 16 27
New learning 17 15 15 18 17 21
Remote 4 4 4 4 0 4
Recent 4 4 4 2 2 4
Memory total 25 23 23 24 19 29
Attention total 8 9 7 8 8 9
Drawing 6 7 6 5 6 8
Actions to command 10 9 9 8 8 10
Praxis total 16 16 15 13 14 18
Abstract thinking total 4 4 2 2 3 6
Perception total 8 8 8 8 8 8
CAMCOG total 94 97 90 92 80 109
*TX 5 No corresponding brain scan data. Maximum score is shown in
the last column for each area.2.2.1. Structural MRI
Across timepoints 1–4, the T1-MPRAGE data were
processed using the longitudinal pipeline of FreeSurfer
to obtain measurements of cortical thickness measure-
ments in 34 region-of-interest per hemisphere, based on
the Desikan-Killiany parcellation scheme [4]. The tech-
nical procedures for surface reconstruction and quantifica-
tion of cortical thickness have been described previously.
Briefly, the process involved automated nonuniformity
bias correction, skull stripping, segmentation of the white
matter, and the boundary between the white and gray mat-
ter. The gray/white boundary served as a starting point for
a deformable surface algorithm to compute the gray/white
and pial surfaces, from which cortical thickness is calcu-
lated as the closest distance from the gray/white matter
boundary to the pial surface at each vertex on the tessel-
lated surface. In addition, PetSurfer was used to segment
additional regions, such as the cerebrospinal fluid, pons,
skull, and air cavities to facilitate partial volume correc-
tion of PET data. Each PET datum was registered to the
resulting template, and partial volume correction was
performed in PetSurfer, consistent with our previous
methodology [5].
2.2.2. [11C]-PiB and [18F]-AV1451 imaging
[11C]-PiB data were acquired in three-dimensional mode
on a GE Advance scanner. Before [11C]-PiB injection,
a 15-minute transmission scan using rotating 68Ge rod
sources was acquired to correct for photon attenuation.[11C]-PiB was produced with high radiochemical purity
(.95%) and specific activity (.150 GBq/umol). [11C]-
PiB was injected as a bolus (median 5 545 MBq, inter-
quartile range 5 465-576 MBq) through an antecubital
venous catheter, and data were acquired for 90 min after
injection in 58 frames (18 ! 5, 6 ! 15 seconds,
10 ! 30 seconds, 7 ! 1 minute, 4 ! 2.5 minutes, and
13 ! 5 minutes). For each frame, sonogram data were re-
constructed using the PROMIS three-dimensional filtered
back-projection algorithm into a 128 ! 128 x 35 image
array with a voxel size of 2.34 ! 2.34 ! 4.25 mm [3].
The dynamic PET images were realigned with statistical
parametric mapping and averaged. The resultant mean im-
ages were coregistered to FreeSurfer-processed T1 data for
quantification in FreeSurfer region-of-interest using Pet-
Surfer. Tau deposition was quantified in vivo using [18F]-
AV-1451 on a GE SIGNA PET/MR scanner. Standardized
uptake value ratio for [18F]-AV-1451 was calculated for
data 75–105 minutes after injection (185 MBq) with the
cerebellum as the reference region. Images (6! 5 minutes;
2.0 ! 2.0 ! 2.8 mm3) were reconstructed using OSEM
(16 subsets, 6 iterations; no smoothing), with a low-dose
CT scan acquired on a GE Discovery 690 PET/CT used
for attenuation correction of the head. Finally, [18F]-AV-
1451 standardized uptake ratio was calculated with the cer-
ebellum as the reference region.3. Result
Throughout the course of the study, the participant was
seen 4 times (2010, 2013, 2015, and 2017). The participant
was enrolled into the study with a diagnosis of mild cogni-
tive impairment. Clinically, he had a history of depressive
symptoms without any behavioral problems. On his initial
assessment (2010), he scored 94/109 on the CAMCOG
(Table 1). Baseline [11C]-PiB scans revealed elevated Ab
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and striatum. Structural MRI revealed no signs of severe at-
rophy with a medial temporal lobe atrophy score of 1
(Fig. 1). At the third visit in 2015, the patient was confirmed
to have clinical dementia. During this period, behavioral
changes emerged, such as a lack of enthusiasm, increased
tendencies for verbal repetition, and stubbornness. Memory
impairments were also noted, which included an increased
difficulty with remembering the locations of items and con-
tent of conversations, and the time of day. Languagewas also
affected, evidenced by an increased difficulty with keeping
up with ordinary conversation and word-finding difficulties
alongside an overall slowing in thinking. The onset of the de-
mentia was preceded by a sharp Ab accumulation, from 0.35
[11C]-PiB non-displaceable binding potential (BPND) at
baseline (2010) to 0.45 [11C]-PiB BPND at T2 (2013), before
Ab reached a plateau at T3 (2015; [11C]-PiB BPND 5 0.45;
Fig. 2). Relative to the baseline [11C]-PiB scan, increased Ab
burden at T2 and T3 was observed in frontoparietal cortices
with relative sparing of the temporal lobe (Fig. 3A). Of note,
the fastest rate of annualized Ab accumulation was esti-
mated to be 0.1 BPND (Fig. 3B). Similarly, structural MRI
revealed progressive atrophy and ventricular dilatation,
although it was most pronounced only at T3 (Fig. 1). Visual
inspection of the [18F]-AV1451 at T4 revealed two main ob-Fig. 1. Trajectory of structural atrophy, Ab accumulation over 3 timepoints and ta
revealed progressive ventricular dilatation and subtle hippocampal atrophy with re
mulation were distributed in posterior regions, such as the precuneus. Over the cou
regions. Bottom row: At T4, [18F]-AV1451 scan showed a stereotypical pattern of A
cortices. Abbreviations: Ab, amyloid b; AD, Alzheimer’s disease; MRI, magneticservations: (i) a stereotypical pattern of elevated tau deposi-
tion, characterized by predominant binding in the bilateral
precuneus and temporoparietal cortices (Fig. 1) and (ii) in
contrast to the often-reported striatal pattern of [11C]-PiB
signal in DS, this region was relatively spared of [18F]-
AV1451 binding (Fig. 1).4. Discussion
In this deep-phenotyping case study of an adult with
DS, we reported a sharp increase in Ab burden that pre-
ceded the onset of clinical dementia and pronounced
decline in memory and language functions, which, in
turn, mapped onto the topography of tau deposition within
the temporoparietal cortex. To the best of our knowledge,
this is the first in vivo demonstration of progressive Ab
accumulation during the process of dementia conversion
from mild cognitive impairment. The close mapping be-
tween AD pathologies and clinical decline further demon-
strates the potential utility for deep-phenotyping studies to
elucidate the temporal relationships between in vivo patho-
logical AD markers in DS.
Of clinical interest, the patient’s transition from a prodro-
mal phase of dementia to dementia was preceded by a sharp
increase in Ab burden (2010–2013). As shown in Fig. 1A,u deposition at timepoint 4. Top row: Across the timepoints, structural MRI
spect to baseline (blue voxels). Middle row: Peak regions of amyloid accu-
rse of study, the spatial extent of amyloid increased to encompass temporal
D tau distribution that involved the bilateral precuneus and temporoparietal
resonance imaging.
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Fig. 2. Contrasting longitudinal trajectories associated with Ab accumulation and cortical thinning across the cortex. The sharp increase of Ab at T2 relative to
T1 was followed by a plateau at T3, whereas cortical thickness continued to decrease across all timepoints. Abbreviation: Ab, amyloid b.
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torhinal cortex, fusiform gyrus, parahippocampal cortex),
whereas others were already close to plateau at baseline
and therefore did change further, but some regions were
captured during the transition, mostly encompassing frontal
and parietal cortical regions. These data showed that the
maximum rate of change was 0.1 [11C]-PiB BPND per
year. One caveat to this estimate, however, is that amyloid
accumulation in DS may occur at a more aggressive rate
than in the general population.
In keeping with hypothetical models of sporadic AD
[6], our data suggest that the dynamic phase of Ab depo-
sition in DS occurs during the prodromal phase and littleFig. 3. Regional distribution of Ab accumulation from baseline to 59 months. A
accumulation in cortical regions. Abbreviation: Ab, amyloid b.change in Ab deposition is expected after the onset of
clinical dementia. This follows that earlier interventions,
ideally in the prodromal phase of DS, are urgently needed
to gain the maximum therapeutic potential of drugs that
target the Ab pathways. We also observed a contrasting
pattern of trajectories between Ab accumulation and brain
atrophy in this patient with DS, where progressive in-
crease in Ab paralleled with cortical thinning over the
course of the study. This coupling between increased am-
yloid and brain atrophy is broadly consistent with our pre-
vious work on a larger cohort of DS. In the absence of
further Ab accumulation at T3, we speculate about the
neuropathological substrates underpinning the worsening: Heatmap of [11C]-PiB BPND across the cortex. B: Annualized rate of Ab
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hyperphosphorylated tau being the prime suspect. Indeed,
the patient with DS showed elevated [18F]-AV1451
binding in the temporoparietal cortices, where we have
recently demonstrated a tight coupling between tau pa-
thology and atrophy in AD [5]. The regional distribution
of tau in our patient with DS also resembled the stereotyp-
ical distribution of tau hyperphosphorylation associated
with AD (see Hall and Mak et al., [7], for a systematic re-
view of tau PET imaging). Further studies, including our
ongoing work in the Neurodegeneration in Aging Down
Syndrome study with tau-tracer [18F]-AV1451 and [11C]-
PiB imaging, will help disentangle the differential contri-
butions of Ab and tau toward brain atrophy and disease
progression.
In summary, this brief report demonstrates the utility for
deep-phenotyping designs to improve our understanding of
the disease course and highlight the potential for multimodal
imaging to elucidate the interactions among AD neuropa-
thologies in driving cognitive dysfunction. Further replica-
tion of these findings would inform future studies and
therapeutic trials for which the DS population is a prime
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1. Systematic review: AdultswithDown syndrome (DS)
often have coexisting Alzheimer’s disease (AD) neu-
ropathologies that are considered to be consequent on
the triplication of chromosome 21.Although there has
been significant progress in our understanding of the
role of amyloid b in the disease course of DS, longitu-
dinal evidence capturing the process of amyloid accu-
mulation and how it relates to worsening cognitive
impairment is still unclear. There are currently no lon-
gitudinal studies or case reports relating in vivo amy-
loid burden or tau deposition to cognitive outcomes.
2. Interpretation: Our case study showed—for the first
time—that a sharp increase in amyloid b preceded
the onset of clinical dementia. In addition, the [18F]-
AV1451 PET scan revealed a stereotypical AD-like
distribution of tau deposition, particularly in the tem-
poroparietal cortices. These observations are consis-
tent with biomarker models in AD and highlight the
potential for deep-phenotyping imaging to disentangle
the contributions of AD neuropathologies in DS.
3. Future directions: Further longitudinal studies are
necessary to clarify the extent to which amyloid b
and tau deposition contribute to subsequent cognitive
decline in DS.References
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